Skip to Content

Bio-Genex Laboratories Inc BGNX Stock Quote

| Rating as of


Market Closed

| Currency in USD

  • Last Close < 0.01
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Investment Style
  • Day Range < 0.01  –  < 0.01
  • Year Range < 0.01  –  < 0.01
  • Market Cap
  • Volume / Avg 951.0 /  801.5
  • Price / Sales
  • Price / Book
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis BGNX

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BGNX

Company Profile BGNX

Business Description

Bio-Genex Laboratories Inc is a United States-based company engaged in the business of designing, developing, and commercializing molecular pathology systems for cancer diagnosis, prognosis, precession medicine, and life science research. Its products include Xmatrx systems, i6000 systems, i500 Plus, EZ-Retriever, IHC primary antibodies, microRNA probes, special stains, and IHC/ISH detection kits, among others. The product areas in which the company focuses are multiple fully automated molecular pathology workstations, Immunohistochemistry, In-situ hybridization, Fluorescence in-situ hybridization, Multiplex stains, In-situ PCR, and MicroRNA and HPV probe systems. The organization has a business presence all around the globe.

48810 Kato Road, Suite 100E & 200E
Fremont, CA, 94538
Industry Diagnostics & Research

Competitors & Peers BGNX

Morningstar does not cover competitors or peers for this firm.

FAQs for Bio-Genex Laboratories Inc Stock

No. BGNX does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

BGNX’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare BGNX’s historical performance against its industry peers and the overall market.